The SYNERGY-AI registry is the first of its kind to combine artificial intelligence, genomic biomarkers and multi-variate analysis to accelerate clinical trial matching and promote access to promising cancer therapies.
“Today’s announcement marks a one-of-a-kind clinical program which utilizes a precision medicine approach to clinical trial matching that could potentially catalyze accelerated enrollment from a patient-driven perspective, while promoting access and innovation” said Dr. Arturo Loaiza-Bonilla, MD, MSEd, chief medical advisor and co-founder of Massive Bio. “Initiation of this study also represents a significant milestone for Massive Bio, as we have the opportunity to help over 1,500 patients to enroll in therapeutic cancer trials. Most importantly, we believe this program has the potential to change the paradigm of how we approach clinical trial screening and enrollment, and help many more patients in the future.”
